The forecast for cardiac glycosides sales in Canada from 2024 to 2028 indicates stability following a decreasing trend from an estimated value of 0.3 USD per capita in 2024 to a steady 0.2 USD per capita from 2025 onwards. This represents a significant drop from 2023 levels, which would need to be higher to reflect the forecasted decline.

Future trends to watch for include:

Potential shifts in healthcare regulations affecting cardiac glycosides usage.
Advancements in medical treatments that could replace or enhance the use of cardiac glycosides.
Changing demographic factors influencing demand.